DMC Biotechnologies
DMC Biotechnologies is a US-based biomanufacturer that produces sustainable specialty chemicals—inositols, amino acids, and chemical intermediates—via its proprietary Dynamic Metabolic Control precision fermentation platform. It serves dietary supplement, cosmetic, and industrial chemical markets through direct sales and channel partners across North America, Europe, and Asia.
- Company typePrivate
- Founded2014
- HeadquartersBoulder, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What DMC Biotechnologies does
DMC Biotechnologies is a US-based biomanufacturer founded in 2014 that produces sustainable, bio-based specialty chemicals using its proprietary Dynamic Metabolic Control™ precision fermentation platform. The technology is a standardized two-stage fermentation process that decouples microbial growth from production via controlled gene silencing and targeted proteolysis, enabling predictable scale-up from high-throughput screening (96-well plates) to commercial volumes and reducing microbe sensitivity to industrial conditions. DMC operates R&D facilities in Morrisville, North Carolina (Research Triangle Park, 9,500 sq ft, opened November 2023) and Boulder, Colorado, and licenses its core synthetic metabolic valve technology exclusively from Duke University.
The company commercializes KeyPura™ Myo-Inositol (launched May 2025) and KeyPura™ D-Chiro-Inositol (launched July 2025) for dietary supplements, nutraceuticals, and cosmetic actives, alongside L-Alanine and branched chain amino acids for nutrition and industrial chemical applications. Revenue is generated through direct enterprise sales and regional distribution partnerships—LBB Specialties in the United States and Canada, SCG Chemicals across ASEAN, plus strategic co-development agreements with Toyobo (Japan) and the Biotech Open Platform with Danone, Michelin, and Crédit Agricole Centre France in Clermont-Ferrand, France. Manufacturing is outsourced to partners including Conagen and EW Biotech (Leuna, Germany), where DMC demonstrated 85,000L commercial-scale L-alanine fermentation.
DMC Biotechnologies firmographics
Firmographics- Name
- DMC Biotechnologies
- Legal name
- DMC Biotechnologies, Inc.
- Website
- https://dmcbio.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- DMC Biotechnologies is a US-based biomanufacturer that produces sustainable specialty chemicals—inositols, amino acids, and chemical intermediates—via its proprietary Dynamic Metabolic Control precision fermentation platform. It serves dietary supplement, cosmetic, and industrial chemical markets through direct sales and channel partners across North America, Europe, and Asia.
- Ownership category
- akta.pro rank
DMC Biotechnologies industry classification
Industry- Product category
- Bio-based specialty chemicals (precision fermentation ingredients)
- NAICS
- Other Basic Organic Chemical Manufacturing (32519), Biological Product (except Diagnostic) Manufacturing (325414), All Other Basic Organic Chemical Manufacturing (325199)
- SIC
- Industrial Organic Chemicals (2860), Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)
- akta.pro secondary industries
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Biochemicals & Bio-based Platform Chemicals (cellulose sugars, lignin derivatives, organic acids) (IMAMALAB)
Keywords
Where DMC Biotechnologies is headquartered
LocationHeadquarters
- HQ city
- Boulder
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
DMC Biotechnologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Infrastructure, Personnel, Marketing or Sales, Supply Chain, Operations
Revenue model
- Bio-based Specialty Chemical Sales: DMC generates revenue by selling proprietary fermentation-produced specialty chemicals and ingredients directly to manufacturers in nutrition, personal care, and industrial chemical markets. Revenue is derived from product sales of inositols, amino acids, and other bio-based chemicals.
- Product Distribution Partnerships: Revenue flows through distribution partnerships where DMC supplies products and partners handle regional distribution and sales. Examples include LBB Specialties for US/Canada and SCG for ASEAN markets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B ingredient sales with custom quotation |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
DMC Biotechnologies product offering
Product offeringCore offering
DMC Biotechnologies designs and sells bio-based specialty chemicals produced via precision fermentation using its proprietary Dynamic Metabolic Control™ technology. Its commercial portfolio includes KeyPura Myo-Inositol and D-Chiro-Inositol for dietary supplements and cosmetic actives, plus L-Alanine and branched chain amino acids for nutrition and bio-based chemical applications. Products are sold as sustainable, fermentation-produced alternatives to conventionally manufactured ingredients for B2B brand owners and formulators.
Product overview
DMC Biotechnologies is a U.S.-based biomanufacturer offering a portfolio of sustainably produced bio-based specialty chemicals through its proprietary Dynamic Metabolic Control precision fermentation technology platform. The company commercializes ingredients across three main markets: dietary supplements and nutraceuticals (KeyPura myo-inositol, KeyPura D-chiro-inositol), cosmetic actives, and bio-based chemicals and monomers (L-alanine, branched chain amino acids). The Dynamic Metabolic Control technology enables standardized, scalable, and predictable fermentation processes that decouple growth from production, allowing DMC to efficiently develop and manufacture multiple products with reduced environmental footprint. The company operates R&D facilities in Research Triangle Park, NC and Boulder, CO, with commercial production partnerships for global distribution.
Differentiator
Problem solved
Functional benefit
Brands
- KeyPura: Brand name for DMC's fermented inositol products including myo-inositol and D-chiro-inositol for dietary supplements, nutraceuticals, and cosmetic actives
Products and services
- KeyPura Myo-Inositol Fermentation-produced myo-inositol for dietary supplements, functional foods, and cosmetic formulations. Supports cellular signaling, metabolic balance, and reproductive health, marketed to health-focused brand owners and formulators seeking a sustainable, naturally produced alternative to conventional myo-inositol.
- KeyPura D-Chiro-Inositol Fermentation-based D-chiro-inositol for women's health, testosterone support, and cardiometabolic health. Plays roles in insulin sensitivity and hormonal regulation, targeting nutraceutical and supplement formulators as an industry-first fermented alternative.
- L-Alanine Versatile chemical intermediate and nutritional supplement produced via precision fermentation. Provides a claimed 90%+ reduction in CO2 emissions compared to conventional chemical routes, supporting sustainable practices and supply chain resilience for nutrition and bio-based chemical applications.
- Branched Chain Amino Acids (BCAAs) Amino acids for human nutrition and other applications, developed and commercialized through DMC's fermentation platform for global markets, including distribution into the ASEAN region via SCG Chemicals.
Quantifiable outcome
- 90%+ CO2 emission reduction for L-alanine production compared to conventional supply chains
- +4 more outcomes
Companies that use DMC Biotechnologies
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
DMC Biotechnologies technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
DMC Biotechnologies partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and flagship.
- LBB SpecialtiescoreLBB Specialties serves as the distributor for DMC's KeyPura™ fermented myo-inositol and D-chiro-inositol in the United States and Canada. The partnership serves Human Nutrition, Food, Personal Care, and Life Science markets, bringing cleaner and more sustainable fermented inositol ingredients to North American customers.
- ToyobocoreMulti-year joint development agreement to develop sustainable, fermentation-produced high-volume chemical intermediates for use in essential materials. Toyobo brings chemical synthesis and biotechnology expertise along with global market access, while DMC contributes Dynamic Metabolic Control™ technology and metabolic engineering capabilities.
- DanoneflagshipPartnership to create the Biotech Open Platform at Center for Sustainable Materials - Parc Cataroux in Clermont-Ferrand, France. Initial investment of over 16 million euro in first phase to develop advanced fermentation processes at larger scale. Danone contributes food industry expertise and commitment to sustainable ingredients.
- MichelinflagshipCo-founder of the Biotech Open Platform at Parc Cataroux Center for Sustainable Materials. Michelin provides the facility infrastructure and supports development of bio-sourced materials as part of its sustainability commitment. Platform aims to accelerate scale-up of precision fermentation for materials innovation.
- ConagencoreManufacturing agreement for commercial production of DMC's first product, L-alanine. Conagen provides fermentation manufacturing capabilities to enable DMC to bring products to market without building own manufacturing infrastructure.
- SCG ChemicalscoreAgreement to bring DMC's L-Alanine and branched chain amino acids into ASEAN markets (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, Vietnam). SCG is a leading chemical company in Southeast Asia with wide regional distribution reach.
- EW BiotechcoreService provider for process development, scale-up, and custom manufacturing of biotechnological processes. EW Biotech's facility in Leuna, Germany hosted DMC's commercial scale demonstration (85m3 fermentation) and downstream processing (6,000+ kg L-alanine purified).
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
DMC Biotechnologies competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
DMC Biotechnologies social profiles
Digital presenceDMC Biotechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
DMC Biotechnologies leadership team
Management profileNumber of profiles
Profiles14 records
DMC Biotechnologies funding detail
Funding detailFunding overview
Funding rounds5 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DMC Biotechnologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DMC Biotechnologies
What does DMC Biotechnologies do?
DMC Biotechnologies designs and sells bio-based specialty chemicals produced via precision fermentation using its proprietary Dynamic Metabolic Control™ technology. Its commercial portfolio includes KeyPura Myo-Inositol and D-Chiro-Inositol for dietary supplements and cosmetic actives, plus L-Alanine and branched chain amino acids for nutrition and bio-based chemical applications. Products are sold as sustainable, fermentation-produced alternatives to conventionally manufactured ingredients for B2B brand owners and formulators.
Is DMC Biotechnologies a public or private company?
DMC Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was DMC Biotechnologies founded?
DMC Biotechnologies was founded in 2014. It employs 51 to 100 people.
Where is DMC Biotechnologies based?
DMC Biotechnologies is headquartered in Boulder, United States, in the North America region.
How does DMC Biotechnologies make money?
Two revenue lines are on record. Bio-based Specialty Chemical Sales are the primary driver. The others are product Distribution Partnerships.
Does DMC Biotechnologies have an API?
No public API is recorded for DMC Biotechnologies.
What industry is DMC Biotechnologies in?
DMC Biotechnologies's product category is Bio-based specialty chemicals (precision fermentation ingredients). Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives, with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 32519 and its SIC code is 2860.